Pfiz­er, Astel­las clinch ex­pand­ed ap­proval for Xtan­di in ear­li­er line of prostate can­cer

Pfiz­er and Astel­las on Thurs­day nabbed an ex­pand­ed ap­proval for Xtan­di (en­za­lu­tamide) to treat non-metasta­t­ic cas­tra­tion-sen­si­tive prostate can­cer with bio­chem­i­cal re­cur­rence …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER